Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 6 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Nanjing Genscript Biotech Co. Ltd. currently has 11 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across multiple distinct examiners, indicating a high level of examiner variety in the company's prosecution docket. The portfolio is active across 6 distinct art units, which reflects a broad technical footprint within the biotechnology field. This distribution suggests the company is pursuing a diverse range of biological technologies that fall under 6 distinct art units.
KENNEDY, SARAH JANE is the busiest examiner with the sole pending office action assigned to her. With various distinct examiners assigned to the cases, no single examiner is handling more than one matter. This one to one ratio between actions and examiners means the applicant must manage separate examiner relationships, requiring a highly individualized approach for each pending matter. The presence of numerous examiners ensures that the outcome of one office action is unlikely to be influenced by the same individual's perspective on another pending case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 2 (18%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 6 (55%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENNEDY, SARAH JANE | 1 | 0.0% | +0.0% |
| BORTOLI, JONATHAN | 1 | 76.3% | +41.2% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| WASHINGTON, BRITNEY NICOLE | 1 | 83.1% | +13.2% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
| FLINDERS, JEREMY C | 1 | 63.5% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396656 | AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR | WASHINGTON, BRITNEY NICOLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18718992 | METHOD FOR DETECTING INTEGRATION SITE | KENNEDY, SARAH JANE | — |
| 18713145 | AUXILIARY CONNECTION DEVICE | BORTOLI, JONATHAN | — |
| 18287245 | PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS | MYERS, CARLA J | — |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | LU, CHENG | — |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | CHONG, KIMBERLY | — |
| 18262420 | METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR | LEITH, NANCY J | — |
| 17624505 | ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758048 | Method For Constructing Gene Mutation Library | FLINDERS, JEREMY C | 8d |
| 18713145 | AUXILIARY CONNECTION DEVICE | BORTOLI, JONATHAN | — |
| 18682827 | ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a | BENAVIDES, JENNIFER ANN | — |
| 18396656 | AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR | WASHINGTON, BRITNEY NICOLE | — |
| 18287245 | PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS | MYERS, CARLA J | — |
| 18286880 | PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF | PERSONS, JENNA L | — |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | LU, CHENG | — |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | CHONG, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1682 | 1 |
| 1637 | 1 |
| 1642 | 1 |
| 1684 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718992 | METHOD FOR DETECTING INTEGRATION SITE | KENNEDY, SARAH JANE | — | §103§112Other | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18713145 | AUXILIARY CONNECTION DEVICE | BORTOLI, JONATHAN | — | §102§103§112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18682827 | ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a | BENAVIDES, JENNIFER ANN | — | §112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18396656 | AUTOMATIC EXTRACTION DEVICE AND USE METHOD THEREFOR | WASHINGTON, BRITNEY NICOLE | — | §103 | Final Rejection | — | Pending | Dec 26, 2023 |
| 18287245 | PRIMER GROUP AND METHOD FOR DETECTING SINGLE-BASE MUTATIONS | MYERS, CARLA J | 1682 | §101§102§103§112DP | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18286880 | PLASMID SYSTEM WITHOUT SELECTABLE MARKERS AND PRODUCTION METHOD THEREOF | PERSONS, JENNA L | 1637 | §102§103§112DPOther | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18281849 | ANTIBODY FUSION PROTEINS AND USES THEREOF | LU, CHENG | 1642 | §103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18262420 | METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR | LEITH, NANCY J | 1636 | §103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 17758048 | Method For Constructing Gene Mutation Library | FLINDERS, JEREMY C | 1684 | §103 | Non-Final OA | 8d | Pending | Jun 27, 2022 |
| 17624505 | ANTI-CD47/ANTI-CTLA-4 BISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112 | Final Rejection | — | Pending | Jan 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial